ArticleCancer causes & control : CCC2025
de novo metastases in patients with primary colorectal cancer: a Surveillance, Epidemiology, and End Results analysis.
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- External validation of a nomogram for de novo bone metastasis in breast cancer: a single-center Mexican cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeNearly one-quarter of colorectal cancer (CRC) cases present with de novo metastatic disease (stage IV) at diagnosis. Some metastatic sites confer poorer prognosis, and emerging data suggests that individuals from certain racial and ethnic populations may be at higher risk for de novo metastases.
methodsWe identified 181,083 CRC cases aged 20-84 between 2010 and 2020 in the Surveillance, Epidemiology, and End Results database. Two outcomes were analyzed: metastatic site (liver, lung, bone, brain) and metastatic pattern (liver only, lung only, liver and lung, other). We used logistic and multinomial logistic regression to calculate odds ratios (OR) and 95% confidence intervals (95% CI) to examine the associations between race and ethnicity and metastatic site and metastatic pattern, respectively, among early-onset (age < 50), screen-eligible (age 50-74), and elderly populations (age 75-84).
results43,054 de novo metastatic CRC cases were identified over the 10-year period. Liver was the most common metastatic site (80%). Non-Hispanic Black patients had higher odds of synchronous lung and liver metastases compared to non-Hispanic White (NHW) patients (early-onset patients: OR: 1.29, 95% CI 1.03-1.61; screen-eligible patients: OR:1.42, 95% CI 1.29-1.55; elderly patients: OR:1.66, 95% CI 1.34-2.05). Early-onset American Indian/Alaska Native patients were over twice as likely to present with lung metastases (OR: 2.10, 95% CI 1.11-3.98) compared to NHW patients.
conclusionsPresentation and patterns of de novo metastatic CRC differed across populations and age groups. Characterizing de novo metastatic CRC provides a unique opportunity to study cancer spread in treatment-naïve individuals and to identify patients at greater risk of metastases associated with poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.